Sysmex’s PA-100 AST System for Rapid Detection of Antimicrobial Susceptibility Wins One of the UK’s Biggest Science Prizes “Longitude Prize on AMR”

Sysmex Corporation is pleased to announce that its subsidiary Sysmex Astrego AB has been awarded one of the UK's biggest science prizes, the “Longitude Prize on AMR,” for the development of the PA-100 AST System, a rapid antimicrobial susceptibility testing system. The prize is designed to reward and support teams of innovators who have undertaken the challenge of transforming the conventional clinical workflows for infectious diseases, thereby making greatest contribution to tackling the global issue of antimicrobial resistance (AMR).1 Since the prize launched in November 2014, more than 250 teams from around the world have applied, with Sysmex Astrego AB standing out as the sole recipient.

Healios Concluded License Agreement with Astellas Pharma Concerning RPE Cell Production Method

HEALIOS K.K. (“Healios”) today announces that it has entered into a License Agreement with Astellas Institute for Regenerative Medicine (“AIRM”, Location: Westborough, MA; President: Erin Kimbrel, PhD), a subsidiary of Astellas Pharma Inc. (Head Office: Chuo-ku, Tokyo; President and CEO: Naoki Okamura), that investigates novel pluripotent stem cell derived therapeutic products, concerning the patent on a Retinal Pigment Epithelial (RPE) cells*1 production method shared with RIKEN, National Research and Development Agency in Japan, and Osaka University, National University Corporation in Japan, and the patent on a method for purification of RPE cells shared with Osaka University (“Patents”)*2. Healios grants AIRM a non-exclusive license in the countries where the patents are filed outside of Japan.